-
RG108 DNA Methyltransferase Inhibitor Workflows
2026-09-18
RG108 provides a non-nucleosidic route to DNMT inhibition for enzyme studies, leukemia-cell experiments, and stem-cell differentiation workflows. Its value is greatest when direct methylation measurements are paired with gene-expression and phenotype readouts.
-
Ferritin Hybrid Vaccine for Influenza and SARS-CoV-2
2026-09-18
Song and colleagues developed a ferritin-based hybrid protein particle that co-displays influenza A M2e and tandem SARS-CoV-2 S-protein epitopes after expression in Escherichia coli. In mice, the hybrid particle produced strong antigen-specific responses and sera with pseudovirus inhibition, M2-expressing cell binding, and antibody-dependent cellular cytotoxicity activity, supporting ferritin as a combination-vaccine platform while leaving important translational questions open.
-
Caffeine as a Mechanistic Assay Stress Test
2026-09-17
Caffeine and 1,3,7-trimethylpurine-2,6-dione can reveal how adenosine signaling, cancer cell line inhibition, and energy metabolism modulation respond to controlled perturbation. This article presents an assay-interpretation framework that distinguishes validated caffeine biology from exploratory comparisons with ALDH2-targeted ischemia research.
-
CH 223191: AhR Antagonist Workflow
2026-09-17
CH 223191 is a practical aryl hydrocarbon receptor antagonist for separating AhR-dependent transcription from upstream toxicant, microbial-metabolite, or tissue effects. This guide translates its validated potency and formulation properties into workflows for dioxin toxicity mechanism studies, intestinal repair assays, and broader environmental toxicology research.
-
Carfilzomib (PR-171): An Assay-First Guide
2026-09-16
Carfilzomib (PR-171) is an irreversible proteasome inhibitor for dissecting how proteostasis failure reshapes cancer-cell death. This assay-first guide translates recent ESCC radiosensitization findings into practical decisions about controls, readouts, formulation, and mechanistic interpretation.
-
Saracatinib (AZD0530): Src Signaling Assay Guide
2026-09-16
Saracatinib (AZD0530) is a dual Src/Abl kinase inhibitor for dissecting cancer signaling and pathway-dependent phenotypes. This guide connects its oncology applications with a rigorous assay framework informed by Reelin–SFK control of synaptic function.
-
TMB for Serology: From Signal to Surveillance
2026-09-15
TMB and 3,3′,5,5′-Tetramethylbenzidine convert HRP-linked immune recognition into a measurable redox signal. This guide moves beyond routine ELISA chemistry to explain how signal control, epitope selection, and geographic validation shape credible Plasmodium vivax surveillance assays.
-
Mtb Rewires BMX–V-ATPase Signaling
2026-09-15
A 2026 Nature Communications study identifies a host–pathogen mechanism in which Mycobacterium tuberculosis secretes Chp2 to promote BMX-dependent phosphorylation of ATP6V1E1, impairing V-ATPase assembly and lysosomal acidification. The work connects this pathway to bacterial persistence in macrophages and mice, supporting BMX signaling as a potential host-directed tuberculosis target while leaving important translational questions unresolved.
-
CAF EV lncRNA Drives HLA-A Loss in Pancreatic Cancer
2026-09-14
The reference study identifies CAF-derived extracellular vesicle lncRNA RP11-161H23.5 as a mediator of pancreatic ductal adenocarcinoma immune evasion. It links this RNA to CNOT4-dependent shortening of the HLA-A mRNA poly(A) tail and proposes engineered extracellular vesicles for siRNA delivery as a therapeutic strategy.
-
GLT-1, CB1-CREB, and Cognitive Recovery After TBI
2026-09-14
A 2025 mouse study links traumatic brain injury to transient loss of astrocytic GLT-1 through a 2-AG–CB1–CREB mechanism, connecting impaired glutamate clearance with neuronal apoptosis and cognitive dysfunction. Its use of AM281 alongside behavioral, histological, and molecular assays provides a pharmacological framework for testing CB1-dependent regulation of excitotoxicity.
-
HyperScribe™ All in One mRNA Synthesis Kit
2026-09-13
The HyperScribe All in One mRNA Synthesis Kit supports controlled ARCA-capped, polyadenylated transcript production for translation, vaccine, and RNA-function studies. This guide goes beyond workflow description to connect transcript design and quality control with the immune-engineering lessons of a 2026 spleen-targeted HCC mRNA vaccine study.
-
Hepatic sEH, Nrf2, and Osteoporosis
2026-09-12
The reference study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppresses Nrf2 signaling, and promotes osteoclast differentiation. By combining clinical samples, ovariectomy-induced osteoporosis, liver-specific knockdown, pharmacological inhibition, transcriptomics, and cell-based assays, the work provides a mechanistic framework for studying lipid–redox control of bone resorption.
-
Simvastatin: HepG2 Lipidomics Workflow
2026-09-11
Simvastatin (Zocor) provides a practical benchmark for linking HMG-CoA reductase inhibition with cholesterol handling, lipid accumulation, and cancer-cell phenotypes. This workflow shows how to combine controlled dosing, orthogonal lipid assays, and untargeted lipidomics while avoiding common solubility and prodrug-activation errors.
-
Molecular Regulation of TRPM3 by Neurosteroids
2026-09-11
The reference study combines cryo-electron microscopy, electrophysiology, molecular dynamics, and mass spectrometry to define how PregS, CIM0216, and primidone regulate the TRPM3 ion channel. Its structures connect ligand-binding sites with channel gating and disease-associated gain-of-function mutations, providing a mechanistic framework for TRPM3-directed analgesic and neurodevelopmental research.
-
PD 0332991 in Gastric Cancer Assembloids
2026-09-10
PD 0332991 (Palbociclib HCl) is examined here as a mechanistic probe for patient-derived gastric cancer assembloids, not simply as a conventional CDK4/6 inhibitor. Learn how stromal context, Rb status, and assay design can reshape interpretation of antiproliferative responses.